SGLT2 Inhibitors across the Spectrum of Severity of CKD

Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1386-1388. doi: 10.2215/CJN.13430820. Epub 2020 Sep 29.
No abstract available

Keywords: KDIGO risk category; SGLT2 inhibitors; chronic kidney disease; empaglflozin.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Double-Blind Method
  • Glucosides
  • Humans
  • Kidney
  • Renal Insufficiency, Chronic* / diagnosis
  • Renal Insufficiency, Chronic* / drug therapy
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin